Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheng Hu

Showing results (1311-1320 of 1,327) with videos related to

Pageof 133
Sort By:
The New Phytologist|July 22, 2014
Climate refugia: joint inference from fossil records, species distribution models and phylogeographyDaniel G Gavin, Matthew C Fitzpatrick, Paul F Gugger, et al.
American Heart Journal|February 22, 2023
Prospective randomized comparison between upgraded '2C3L' vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial designXiao-Xia Liu, Qiang Liu, Yi-Wei Lai, et al.
International Journal of Biological Sciences|November 7, 2017
Distinct Effects of Ca<sup>2+</sup> Sparks on Cerebral Artery and Airway Smooth Muscle Cell Tone in Mice and HumansQing-Yang Zhao, Yong-Bo Peng, Xiao-Jing Luo, et al.
Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Pageof 133

Showing results (1311-1320 of 1,327) with videos related to

Sort By:
Pageof 133
The New Phytologist|July 22, 2014
Climate refugia: joint inference from fossil records, species distribution models and phylogeographyDaniel G Gavin, Matthew C Fitzpatrick, Paul F Gugger, et al.
American Heart Journal|February 22, 2023
Prospective randomized comparison between upgraded '2C3L' vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial designXiao-Xia Liu, Qiang Liu, Yi-Wei Lai, et al.
International Journal of Biological Sciences|November 7, 2017
Distinct Effects of Ca<sup>2+</sup> Sparks on Cerebral Artery and Airway Smooth Muscle Cell Tone in Mice and HumansQing-Yang Zhao, Yong-Bo Peng, Xiao-Jing Luo, et al.
Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b StudyYuankai Shi, Shiman Wu, Ke Wang, et al.
Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
Pageof 133